SmallCapReview.com has been a leading site for information on small cap stocks, penny stocks and microcaps since 1999, to receive the free SmallCapReview newsletter and be entered to win a Free iPod Touch visit http://www.smallcapreview.com.
Science Applications International Corporation (NYSE: SAI) $15.18. Today announced that it was awarded a new contract by the U.S. Army Intelligence and Security Command (INSCOM) to provide a full range of multi-discipline intelligence services in support of Army intelligence operations. The multiple award, indefinite-delivery/indefinite-quantity (IDIQ) contract has a one-year base period of performance, four one-year options, and a ceiling value of $492 million for all awardees. Work will be performed at Fort Belvoir, Va., and at other locations as required.
The U.S. Army Intelligence and Security Command is the Army's operational intelligence force. INSCOM conducts multi-disciplined (signals intelligence, counterintelligence, human intelligence, geospatial intelligence, measurement and signature Intelligence, biometrics) and all-source intelligence operations to include collection, analysis, production, and dissemination; network warfare operations; information operations; knowledge management for the Army intelligence enterprise; and delivers specialized quick reaction capabilities, advanced skills training, and linguist support for deployed forces to enable battle command in support of full-spectrum Army, Joint, Coalition, and Interagency world-wide operations.
What They Do: SAIC is a FORTUNE 500 scientific, engineering, and technology applications company that uses its deep domain knowledge to solve problems of vital importance to the nation and the world, in national security, energy and the environment, critical infrastructure, and health.
Chelsea Therapeutics International (Nasdaq: CHTP) $4.04. Today announced confirmation by the U.S. Food and Drug Administration (FDA) that its proposed Phase II protocol for CH-4051 in rheumatoid arthritis has been approved by the agency. Chelsea plans to initiate patient screening next month and initiating treatment in October.
This multi-national, double-blind, randomized Phase II trial of CH-4051, an orally available metabolically stable antifolate, is intended to evaluate the safety and efficacy of CH-4051 in a 250-patient head-to-head study against methotrexate (MTX). Patients with rheumatoid arthritis who are experiencing an inadequate response to MTX treatment will be randomized to receive daily oral doses of 0.3 mg, 1.0 mg, 3.0 mg or 3.0 mg plus folate of CH-4051 or 20 mg weekly dose of MTX plus folate supplement for 12 weeks following a two-week MTX-washout. The primary efficacy analysis will be conducted using the hybrid American College of Rheumatology, or ACR, score (hACR), which allows for a more comprehensive assessment of treatment benefit across all seven symptomatic and functional components of the standard ACR 20/50/70 evaluations historically used in RA trials.
What They Do: Chelsea Therapeutics is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases.
Digital Ally, Inc. (Nasdaq: DGLY) $1.70. Today announced the receipt of the first order for DVM-750 In-Car Digital Video Systems under a statewide contract from the state's Sheriff's Association that represents 59 agencies throughout the state. The value of the order, which should be shipped to the customer in the current quarter, is approximately $750,000.
"We are pleased to announce this significant order under the terms of a statewide contract, which reflects the customer's satisfaction with, and enthusiasm for, our flagship DVM-750 In-Car Digital Video System," stated Stanton E. Ross, Chief Executive Officer of Digital Ally, Inc. "We expect to receive additional orders from other law enforcement agencies in this state between now and the end of the current year.
What They Do: Digital Ally, Inc. develops, manufactures and markets advanced technology products for law enforcement, homeland security and commercial security applications.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit http://www.smallcapreview.com.
